JW (Cayman) Therapeutics Co. Ltd

HKSE 2126.HK

JW (Cayman) Therapeutics Co. Ltd Net Cash Used Provided By Financing Activities for the year ending December 31, 2023: USD 38.73 K

JW (Cayman) Therapeutics Co. Ltd Net Cash Used Provided By Financing Activities is USD 38.73 K for the year ending December 31, 2023, a -99.76% change year over year. Net cash used/provided by financing activities are the total cash inflows and outflows related to activities that finance the company’s operations, including debt, equity, and dividends.

JW (Cayman) Therapeutics Co. Ltd Net Cash Used Provided By Financing Activities for the year ending December 31, 2022 was USD 16.28 M, a 437.85% change year over year.
JW (Cayman) Therapeutics Co. Ltd Net Cash Used Provided By Financing Activities for the year ending December 31, 2021 was USD -4.82 M, a -101.10% change year over year.
JW (Cayman) Therapeutics Co. Ltd Net Cash Used Provided By Financing Activities for the year ending December 31, 2020 was USD 438.06 M, a 636.77% change year over year.
JW (Cayman) Therapeutics Co. Ltd Net Cash Used Provided By Financing Activities for the year ending December 31, 2019 was USD 59.46 M, a 63.68% change year over year.

Key data

Date	Net Cash Used Provided By Financing Activities	Dividends Paid	Capital Expenditure	Effect Of Forex Changes On Cash

HKSE: 2126.HK

JW (Cayman) Therapeutics Co. Ltd

CEO	Mr. Min Liu
IPO Date	Nov. 3, 2020
Location	China
Headquarters	Building B
Employees	323
Sector	Healthcare
Industries Biotechnology 3D Printing Autonomous Driving Pharmaceuticals

Description

JW (Cayman) Therapeutics Co. Ltd, a clinical stage cell therapy company, focuses on developing, manufacturing, and commercializing cell-based immunotherapies for hematological cancers and solid tumors. The company offers cell-based immunotherapies, including CAR-T treatments, which is a treatment method that uses human immune cells to fight cancer. Its lead product candidate is Carteyva (relmacabtagene autoleucel), an anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy for the treatment of a range of hematological cancers. The company's pipeline products include JWCAR129, an autologous CAR-T therapy for the treatment of multiple myeloma; JWATM204, a TCR T-cell therapy candidate for the treatment of HCC; and JWATM203, an autologous T-cell receptor mimic T-cell therapy targeting alpha-fetoprotein for the treatment of hepatocellular carcinoma. JW (Cayman) Therapeutics Co. Ltd was founded in 2016 and is headquartered in Shanghai, the People's Republic of China.

Key trends

Past 5 years